3D Systems Corporation (NYSE:DDD) announced that it has completed its acquisition of all shares of Cimatron Ltd. for approximately $97 million, inclusive of Cimatron’s net cash. On Tuesday shares of 3D Systems Corporation (NYSE:DDD) closed at $29.77. Company’s sales growth for last 5 years was 29.90% and EPS growth for next 5 years is recorded as 21.33%.
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) announced that it will report financial results for the fourth quarter and year ending December 31, 2014 on Thursday, February 12, 2015, after the U.S. financial markets close. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in last trading activity moved up 5.93% to close at $93.01. Company weekly performance is 4.68% while its quarterly performance stands at -2.95%. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is -16.58% away from its 52 week high.
On February 2, Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) said the company has completed enrollment in its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. All patients that completed the trial have opted to continue to receive PRX-102 in an open-label extension trial. On last trading day Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) moved up 1.04% to close at $1.94. Its volatility for the week is 4.58% while volatility for the month is 5.21%. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) monthly performance is -15.28%.
On February 6, CEL-SCI Corporation (NYSEMKT:CVM) reported financial results for the quarter ended December 31, 2014. CEL-SCI’s net loss available to common shareholders for the quarter ended December 31, 2014 was ($7,845,318) or ($0.09) per basic share, versus ($5,451,865) or ($0.11) per basic share during the quarter ended December 31, 2013. CEL-SCI Corporation (NYSEMKT:CVM) has 16.70% insider ownership while its institutional ownership stands at 8.10%. In last trading activity company’s stock closed at $0.89.
On February 3, Sanofi and MannKind Corp. (NASDAQ:MNKD) announced that Afrezza (insulin human) Inhalation Powder, the only inhaled insulin, is now available by prescription at U.S. retail pharmacies nationwide. MannKind Corp. (NASDAQ:MNKD) in last trading activity advanced 0.93% to close at $7.58. Company weekly performance is 16.62% while its quarterly performance stands at 31.14%. MannKind Corp. (NASDAQ:MNKD) is -33.97% away from its 52 week high.